Total raised
$1.0M
Last: Seed 2014-01
Stage
Seed
Founded
2014
Headcount
6
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
OphRx is developing eye drops based on noninvasive drug delivery that utilize lyotropic liquid crystals as an alternative to current delivery modalities, such as intra-vitreal injections, used to treat diseases at the back of the eye. This platform technology can also be used for front-of-the-eye treatments. OphRx is currently in the preclinical stage of development of two product candidates: OPH-101, an alternative topical treatment to intravitreal injections for wet AMD; and OPH-100, a treatment for DES. OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.
Funding history · 1 round · $1.0M total
2014-01
Seed
$1.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Tags
healthcare-providersclinicsdoctorstopical-treatmentnanotechnologypharmaceuticalsophthalmologyeye-diseasesnon-invasivepharma-companiesglaucomamedical-technologiesdrug-delivery